Cases & Deals

  • Home
  • Practices
  • Isis expands patent portfolio related to bicyclic nucleic acids (BNAs) and antisense oligomers containing BNAs

Share

Isis expands patent portfolio related to bicyclic nucleic acids (BNAs) and antisense oligomers containing BNAs

February 2008

Clients Isis Pharmaceuticals, Inc.

Jones Day represents Isis Pharmaceuticals, Inc. with the management and development of a patent portfolio related to bicyclic nucleic acids (BNAs) and antisense oligomers containing BNAs.

Contacts

We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.